PeptideCompareThymalin — EU research guide.
Thymalin is a polypeptide extract from bovine thymus, used in Russian clinical practice since the 1980s as an immunomodulator. Research focuses on thymic function restoration, immune senescence and longevity.
What is Thymalin?
Thymalin is a complex preparation of low-molecular-weight polypeptides isolated from bovine thymus. Unlike synthetic single-sequence bioregulators, it is a mixture standardised by biological activity. It has been used as a registered drug in Russia for decades under the name Timalin. In the EU it has no registered pharmaceutical status.
What does the research show?
Russian longitudinal studies in elderly cohorts (some spanning 6–8 years) report reduced mortality, improved immune function markers (T-cell counts, NK activity) and slower immune senescence in thymalin-treated groups versus controls. A notable long-term study showed ~2.0x mortality reduction over 6 years in an elderly cohort. Western replication is absent; all evidence is Russian-origin.
EU legal status
Not approved in the EU as a medicine. Available as a research compound from specialist vendors. Note: being a biological extract, batch consistency is an important quality concern — ensure vendors provide bioactivity standardisation data.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ Computed from molecular properties (sequence length, cyclisation, residues prone to oxidation or deamidation, light sensitivity), per compound. Indicative only — not lab-measured per batch.
Thymalin across EU suppliers
COA-verified EU vendors · Updated monthly